Immvira nets $58m Series B
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination